Adverum Reports Data From Phase I Wet AMD Study, Stock Down
Zacks Investment Research | Sep 12, 2019 10:06PM ET
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced data from cohort 1 of the phase I study — OPTIC — evaluating its gene therapy candidate, ADVM-022, in patients with wet age-related macular degeneration (“AMD”).
The cohort 1 of the study was evaluating a one-time intravitreal 6 x 10^11 vg/eye dose of ADVM-022 to observe patients for vision maintenance and improvements in retinal anatomy over a period of 24 weeks. Data from the study showed that the therapy was safe and well tolerated. Meanwhile, patients treated with ADVM-022 achieved sustained improvements in retinal anatomy and did not require anti-VEGF rescue injections. The patients enrolled in the study had previously required frequent anti-VEGF injections to avoid loss of vision.
Moreover, ADVM-022 achieved a mean change of -2 letters in best corrected visual acuity and a mean reduction of 52.7 micrometer in central retinal thickness.
Although data suggests that treatment with ADVM-022 was generally positive, it also resulted in mild adverse events in all patients and different types of inflammation was observed in most of them.
Shares of Adverum plunged more than 50% on Sep 12, following study data readout. However, the company’s shares are up 89.3% so far this year against the industry ’s decrease of 1.3%.
We note that the company is evaluating a lower dose of 2 x 10^11 vg/eye in cohort 2 of the OPTIC study. Data from the study will likely demonstrate whether a lower dosage of ADVM-022 will lead to a reduction in inflammation events in patients.
We remind investors that the candidate was granted Fast Track designation by the FDA for wet AMD in September 2018.
The development of this candidate is crucial for the company as it discontinued the development of ADVM 043, a gene-therapy candidate for the treatment of alpha-1 antitrypsin (A1AT) deficiency, in November 2018.
The company is planning to develop ADVM-022 in diabetic retinopathy. It also has collaboration agreements with Editas Medicine (NASDAQ:EDIT) and Regeneron Pharmaceuticals (NASDAQ:REGN) for other candidates.
The market potential of wet AMD is significant as it is a leading cause of vision loss in patients above 60 years of age. There are approximately 1.2 million individuals in the United States and 3 million globally affected by wet AMD. Approximately 150,000 to 200,000 people are estimated to be affected by wet AMD in the United States every year.
We note that Novartis (NYSE:NVS) is also developing a therapy targeting wet AMD. In April, the FDA has granted priority review to Novartis’ Biologics License Application seeking approval for brolucizumab as a treatment for wet AMD.
Get The News You Want
Adverum Biotechnologies, Inc. Price
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.